Related Experiment Video
Updated: Apr 5, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and
Jacoba P Greving1,2, Hans-Christoph Diener3, László Csiba4
1Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Insights
This study analyzes individual patient data from six trials to clarify antiplatelet therapy benefits and risks after cerebral ischemia. It aims to guide clinicians in choosing the best antiplatelet regimen for stroke prevention.
Area of Science:
- Neurology
- Clinical Trials
- Pharmacology
Background:
- Uncertainty exists regarding the optimal antiplatelet regimen for patients experiencing cerebral ischemia.
- Antiplatelet drugs reduce stroke risk but require careful risk-benefit assessment for individual patients.
Purpose of the Study:
- To provide clinicians with evidence-based guidance on antiplatelet therapy alternatives after cerebral ischemia.
- To analyze individual patient data from major randomized trials to address therapeutic uncertainties.
Main Methods:
- Meta-analysis of individual patient data from six large randomized trials (46,948 patients) involving antiplatelet therapy for cerebral ischemia.
- Utilizing unique access to all trial data, including participation from key investigators and pharmaceutical companies.
Main Results:
- Estimating the efficacy of various antiplatelet regimens on vascular events, ischemic events, and bleeding complications (major bleeding, intracranial hemorrhage).
- Developing prognostic and decision models to support evidence-based selection of antiplatelet treatments for different patient risk profiles.
Conclusions:
- The study outlines the methodology, including inclusion criteria, outcome measures, baseline data, and planned statistical analyses.
- The findings will inform clinical decision-making regarding antiplatelet therapy in patients with a history of cerebral ischemia.
Background:
The Cerebrovascular Antiplatelet Trialists' Collaborative Group was formed to obtain and analyze individual patient data from the major randomized trials of common antiplatelet regimens after cerebral ischemia. Although the risk of stroke can be reduced by antiplatelet drugs, there continues to be uncertainty about the balance of risk and benefits of different antiplatelet regimens for an individual patient.
Aims:
Our aim is to provide clinicians with a thorough evidence-based answer on these therapeutic alternatives.
Methods:
We have identified six large randomized trials and plan to meta-analyze the data on an individual patient level. In total, these trials have enrolled 46 948 patients with cerebral ischemia. Uniquely, the Cerebrovascular Antiplatelet Trialists' Collaborative Group has secured access to the individual data of all of these trials, with the participation of key investigators and pharmaceutical companies. Our principal objective includes deriving a reliable estimate of the efficacy of different antiplatelet regimens on key outcomes including serious vascular events, major ischemic events, major bleeding, and intracranial hemorrhage.
Results:
We propose to redefine composite outcome events, if necessary, to achieve comparability. Further, we aim to build and validate prognostic models for the risk of major bleeding and intracranial hemorrhage and to build a decision model that may support evidence-based decision making about which antiplatelet regimen would be most effective in different risk groups of patients.
Conclusions:
This paper outlines inclusion criteria, outcome measures, baseline characteristics, and planned statistical analysis.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management